Pieternella J. Lugtenburg
彼得内拉·卢格滕堡
MD, PhD
Professor of Hematology and Lymphoma Specialist血液学教授兼淋巴瘤专家
👥Biography 个人简介
Professor Pieternella Lugtenburg is a leading Dutch lymphoma specialist with deep expertise in follicular and marginal zone lymphomas. She was a principal investigator in the GALLIUM trial evaluating obinutuzumab versus rituximab in previously untreated follicular lymphoma and has been centrally involved in developing bispecific antibody trials for indolent B-cell lymphomas. Her clinical research on mosunetuzumab in relapsed/refractory follicular lymphoma has contributed to the FDA approval of this agent in 2022. She leads lymphoma clinical trials within the HOVON cooperative group.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma
Served as a key investigator in the pivotal GO29781 trial of mosunetuzumab in r/r follicular lymphoma, providing evidence that led to FDA approval in December 2022 as the first bispecific antibody for this indication.
GALLIUM Trial — Obinutuzumab
Contributed as a national principal investigator to the GALLIUM phase III trial, which demonstrated improved progression-free survival with obinutuzumab plus chemotherapy over rituximab plus chemotherapy as first-line therapy in follicular lymphoma.
Marginal Zone Lymphoma Clinical Trials
Designed and conducted HOVON cooperative group trials exploring ibrutinib and lenalidomide-rituximab in marginal zone lymphoma subtypes, with a focus on MALT lymphoma and splenic marginal zone lymphoma.
Representative Works 代表性著作
Mosunetuzumab shows durable efficacy in patients with relapsed or refractory follicular lymphoma after ≥2 prior lines of therapy
Journal of Clinical Oncology (2022)
Key efficacy and safety data supporting FDA approval of mosunetuzumab in r/r follicular lymphoma.
Obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma (GALLIUM)
New England Journal of Medicine (2017)
Phase III trial establishing obinutuzumab combinations as a new first-line standard for follicular lymphoma.
Lenalidomide plus rituximab in marginal zone lymphoma: results of the HOVON 135 MZL trial
Haematologica (2023)
Prospective Dutch cooperative group study of R² in marginal zone lymphoma subtypes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-20 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 彼得内拉·卢格滕堡 的研究动态
Follow Pieternella J. Lugtenburg's research updates
留下邮箱，当我们发布与 Pieternella J. Lugtenburg（Erasmus MC Cancer Institute, Rotterdam）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment